183 related articles for article (PubMed ID: 18613804)
1. The safety of celecoxib in ankylosing spondylitis treatment.
Poddubnyy DA; Song IH; Sieper J
Expert Opin Drug Saf; 2008 Jul; 7(4):401-9. PubMed ID: 18613804
[TBL] [Abstract][Full Text] [Related]
2. Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study.
Kristensen LE; Jakobsen AK; Askling J; Nilsson F; Jacobsson LT
Arthritis Care Res (Hoboken); 2015 Aug; 67(8):1137-49. PubMed ID: 25623277
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
McCormack PL
Drugs; 2011 Dec; 71(18):2457-89. PubMed ID: 22141388
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug.
Dougados M; Béhier JM; Jolchine I; Calin A; van der Heijde D; Olivieri I; Zeidler H; Herman H
Arthritis Rheum; 2001 Jan; 44(1):180-5. PubMed ID: 11212158
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.
Sieper J; Klopsch T; Richter M; Kapelle A; Rudwaleit M; Schwank S; Regourd E; May M
Ann Rheum Dis; 2008 Mar; 67(3):323-9. PubMed ID: 17616556
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
Mallen SR; Essex MN; Zhang R
Curr Med Res Opin; 2011 Jul; 27(7):1359-66. PubMed ID: 21561397
[TBL] [Abstract][Full Text] [Related]
7. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial.
Wanders A; Heijde Dv; Landewé R; Béhier JM; Calin A; Olivieri I; Zeidler H; Dougados M
Arthritis Rheum; 2005 Jun; 52(6):1756-65. PubMed ID: 15934081
[TBL] [Abstract][Full Text] [Related]
8. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM
Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
Jansen JP; Gaugris S; Choy EH; Ostor A; Nash JT; Stam W
Pharmacoeconomics; 2010; 28(4):323-44. PubMed ID: 20222755
[TBL] [Abstract][Full Text] [Related]
10. [Safety of celecoxib administration].
Babić-Naglić D
Reumatizam; 2002; 49(2):26-8. PubMed ID: 12476757
[TBL] [Abstract][Full Text] [Related]
11. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs.
Niculescu L; Li C; Huang J; Mallen S
Curr Med Res Opin; 2009 Mar; 25(3):729-40. PubMed ID: 19210159
[TBL] [Abstract][Full Text] [Related]
12. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
Hochberg MC
Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
[TBL] [Abstract][Full Text] [Related]
13. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
Goldstein JL; Silverstein FE; Agrawal NM; Hubbard RC; Kaiser J; Maurath CJ; Verburg KM; Geis GS
Am J Gastroenterol; 2000 Jul; 95(7):1681-90. PubMed ID: 10925968
[TBL] [Abstract][Full Text] [Related]
14. Celecoxib: new indication. Ankylosing spondylitis: no pain justifies the use of a cox-2 inhibitor. Patients still exposed to unjustified risks.
Prescrire Int; 2008 Jun; 17(95):106. PubMed ID: 18627117
[No Abstract] [Full Text] [Related]
15. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G;
Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
[TBL] [Abstract][Full Text] [Related]
16. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis.
Barkhuizen A; Steinfeld S; Robbins J; West C; Coombs J; Zwillich S
J Rheumatol; 2006 Sep; 33(9):1805-12. PubMed ID: 16960941
[TBL] [Abstract][Full Text] [Related]
17. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM
Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261
[TBL] [Abstract][Full Text] [Related]
18. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor.
Whelton A; Maurath CJ; Verburg KM; Geis GS
Am J Ther; 2000 May; 7(3):159-75. PubMed ID: 11317165
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib clinical profile.
Tive L
Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():21-8; discussion 57-9. PubMed ID: 11276798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
